The efficacy of caffeine in restoring cognitive declines across 24 hours of sustained wakefulness

Not Applicable

• Conditions: Cognitive performance; Sleep; Public Health - Other public health; Neurological - Studies of the normal brain and nervous system

• Registration Number: ACTRN12622001503718
• Lead Sponsor: Australian Catholic University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-12-02
• Last Update Posted: 29 January 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Healthy male and females aged between 18 and 40 years
No reported medical or sleep condition
Daily habitual caffeine consumption <300 mg

Exclusion Criteria

The use of cigarettes, drugs, or medications known to affect sleep in the three months prior to study admission.
Undertaken shift work or transmeridian travel in the month prior to study admission.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Psychomotor Vigilance Task: Response time (ms)[ Measured at 10, 12, 14, 16 (1 h post first dose), 18 (3 h post first dose), 20 (5 h post first dose/1 h post second dose), 22 (7 h post first dose/3 h post second dose), and 24 h (9 h post first dose/5 h post second dose) post wake.];Psychomotor Vigilance Task: Number of lapses (latency >500ms)[ Measured at 10, 12, 14, 16 (1 h post first dose), 18 (3 h post first dose), 20 (5 h post first dose/1 h post second dose), 22 (7 h post first dose/3 h post second dose), and 24 h (9 h post first dose/5 h post second dose) post wake.];Psychomotor Vigilance Task: Number of errors (count)[ Measured at 10, 12, 14, 16 (1 h post first dose), 18 (3 h post first dose), 20 (5 h post first dose/1 h post second dose), 22 (7 h post first dose/3 h post second dose), and 24 h (9 h post first dose/5 h post second dose) post wake.]